Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa

Thrombosis and Haemostasis

Volumn 79, Issue 3, 1998, Pages 543-548

  Taniuchi, Yuta ^a   Sakai, Yumiko ^a   Hisamichi, Nami ^a   Kayama, Makoto ^a   Mano, Yuji ^a   Sato, Kazuo ^a   Hirayama, Fukushi ^a   Koshio, Hiroyuki ^a   Matsumoto, Yuzo ^a   Kawasaki, Tomihisa ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; THROMBIN; UNCLASSIFIED DRUG; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; HUMAN; MONKEY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; THROMBOCYTE AGGREGATION;

EID: 0031888018     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614941     Document Type: Article

References (31)

1. Klement P, Borm A, Hirsh J, Maraganore J, Wilson G, Weitz J. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model. Thromb Haemost 1992; 68: 64-8.
2. Lynch JJ Jr, Sitko GR, Lehman ED, Vlasuk GP. Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model. Thromb Haemost 1995; 74: 640-5.
3. Kelly AG, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77: 1006-12.
4. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin-or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994; 72: 381-6.
5. Maffrand JP. Direct thrombin inhibitors. Nouv Rev Fr Hematol 1992; 34: 405-19.
6. Tapparelli C, Metternich R, Ehrhardt C, Cook NS. Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. Trends in Pharmacol Sci 1993; 14: 366-76.
7. Davie EW, Fujikawa K. Basic mechanisms in blood coagulation. Ann Rev Biochem 1975; 44: 799-829.
8. Radcliffe R, Nemerson Y. Activation and control of factor VII by activated factor X and thrombin. J Biol Chem 1975; 250: 388-95.
9. Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 1995; 92: 962-7.
10. Schaffer LW, Davidson JT, Vlasuk GP, Siegl PK. Antithrombotic efficacy of recombinant tick anticoagulant peptide: a potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 1991; 84: 1741-8.
11. Hara T, Yokoyama A, Tanabe K, Ishihara H, Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 1995; 74: 635-9.
12. Tuszynski GP, Gasic TB, Gasic GJ. Isolation and characterization of antistatin. J Biol Chem 1987; 262: 9718-23.
13. Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593-6.
14. Neeper MP, Waxman L, Smith DE, Schulman CA, Sardana M, Ellis RW, Schaffer LW, Siegel PKS, Vlasuk GP. Characterization of recombinant tick anticoagulant peptide: A highly selective inhibitor of blood coagulation factor XA. J Biol Chem 1990; 265: 17746-52.
15. Vlasuk GP, Ramjit D, Fujita T, Dunwiddie CT, Nutt Em, Smith DE, Shebuski RJ. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistatin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost 1991; 65: 257-62.
16. Sitko GR; Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk FP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide: comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992; 85: 805-15.
17. Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1993; 71: 314-9.
18. Yamazaki M, Asakura H, Aoshima K, Saito M, Jokaji H, Uotani C, Kumabashiri I, Morishita E, Ikeda T, Matsuda T. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats. Thromb Haemost 1994; 72: 393-6.
19. Herbert JM, Bernat A, Dol F, Hérault JP, Crépon B, Lormeau JC. DX-9065a, a novel, synthetic, selective and orally active inhibitor of factor Xa: In vitro and in vivo studies. J Pharmacol Exper Ther 1996; 276: 1030-8.
20. Yamashita T, Tsuji T, Matsuoka A, Giddings JC, Yamamoto J. The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on the He-Ne laser-induced thrombosis in rat mesenteric microvessels. Thromb Res 1997; 85: 45-51.
21. Lineweaver H, Burk D. Determination of enzyme dissociation constants. J Am Chem Soc 1934; 56: 658-66.
22. Dixon M. The determination of enzyme dissociation constants. Biochem J 1953; 55: 170-1.
23. Hackeng TM, van't Veer C, Meijers JCM, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994; 269: 21051-8.
24. Katagiri Y, Hayashi Y, Yamamoto K, Tanoue K, Kosaki G, Yamazaki H. Localization of von Willebrand factor and thrombin-interactive domains on human platelet glycoprotein Ib. Thromb Haemost 1990; 63: 122-6.
25. Dunwiddie C, Thronberry NA, Bull HG, Sardana M, Friedman PA, Jacobs JW, Simpson E, Antistatin, a leech-derived inhibitor of factor Xa. J Biol Chem 1989; 264: 16694-9.
26. Nutt EM, Jain D, Lenny AB, Schaffer R, Siegl PK. Purification and characterization of recombinant antistatin: A leech-derived inhibitor of coagulation of factor Xa. Arch Biochem Biophys 1991; 285: 37-44.
27. Hara T, Yokoyama A, Morishima Y, Kunitada S. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb Res 1995; 80: 99-104.
28. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem 1979; 254: 10952-62.
29. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-83.
30. Jackson CV, Crowe VG, Frank JD, Wilson HC, Coffman WJ, Utterback BG, Jakubowski JA, Smith F. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methylphenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 1992; 261: 546-52.
31. Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA. Antithrombotic effect of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation 1995; 92: 485-91.